Partner With Us NRI

Neuland Laboratories Ltd

Company details

6M Return 15.23%
1Y Return 0.97%
Mkt Cap.(Cr) 1,911.93
Volume 1,618
Div Yield 0.34%
OI Chg %
Volume 1,618

Open Free Demat Account Online with ICICIDIRECT

Neuland Laboratories Ltd.

Q4FY22 Quarterly Result Announced for Neuland Laboratories Ltd.

Pharmaceuticals firm Neuland Laboratories declares Q4FY22 result:

  • Neuland FY22 income at Rs.953.2 crore
  • EBITDA at Rs. 144.3 crore

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “The past financial year was marked by a flat revenue, owing principally to weak GDS offtake from our customers. Given our focus on building execution excellence, we remain confident about the long-term prospects of all our businesses despite facing certain technical issues with some late-stage CMS projects.”

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added “Our performance this year was a mixed bag. While our GDS business experienced a revenue decrease due to volume drop in certain key products, our input cost structures experienced an unusual increase. Given our focus on delivering complex projects in line with clients’ technical requirements, we retain our optimism that the overall business will grow in line with our stated expectations and reflect increased margins over the long term.”

Result PDF

View Other Company Results



Operating Profit

Profit after Tax


Reserves and Surplus



Operating Profit

Profit after Tax






Equity Capital: 840.50 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 9,798.25 -25,291.97
LAST 3M 27,044.95 -25,544.90
LAST 6M 49,131.67 47,902.81
LAST 12M 178,925.96 -114,950.83


Stock PE (TTM)


Promoter Holding


Book Value







  • Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.`92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. It came out with its initial public offering in Apr.`94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr. NLL`s products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate. During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form. Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI. The company is closely working with several companies in Europe and North America for supply of active pharmaceutical ingredients and intermediates.

Registered Address

11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035

Tel : 91-40-30211600
Email : ir:neulandlabs.com
Website : http://www.neulandlabs.com


Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524558
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE794A01010

ICICIdirect Neuland Laboratories Ltd FAQ

You can buy Neuland Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Neuland Laboratories Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jan 31, 2023 04:01 PM the closing price of Neuland Laboratories Ltd was ₹ 1,490.20.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jan 31, 2023 04:01 PM, the market cap of Neuland Laboratories Ltd stood at ₹ 1,911.93.
The latest PE ratio of Neuland Laboratories Ltd as of Jan 31, 2023 04:01 PM is 22.86
The latest PB ratio of Neuland Laboratories Ltd as of Jan 31, 2023 04:01 PM is 0.46
The 52-week high of Neuland Laboratories Ltd is ₹ 2,004.05 while the 52-week low is ₹ 965.85

Download Our App

market app
market app